NDC 0187-0004

Siliq

Brodalumab

Siliq is a Subcutaneous Injection in the Human Prescription Drug category. It is labeled and distributed by Bausch Health Us Llc. The primary component is Brodalumab.

• Product ID: 0187-0004_48009d83-195a-44fe-a8ee-1a006e0e02ea
• NDC: 0187-0004
• Product Type: Human Prescription Drug
• Proprietary Name: Siliq
• Generic Name: Brodalumab
• Dosage Form: Injection
• Route of Administration: SUBCUTANEOUS
• Marketing Start Date: 2017-02-15
• Marketing Category: BLA / BLA
• Application Number: BLA761032
• Labeler Name: Bausch Health US LLC
• Substance Name: BRODALUMAB
• Active Ingredient Strength: 210 mg/1
• Pharm Classes: Interleukin-17 Receptor A Antagonist [EPC],Interleukin 17 Receptor A Antagonists [MoA],Antibodies, Monoclonal [CS]
• NDC Exclude Flag: N
• Listing Certified Through: 2021-12-31

Packaging

NDC 0187-0004-02

2 SYRINGE in 1 CARTON (0187-0004-02) > 1 INJECTION in 1 SYRINGE (0187-0004-00)

• Marketing Start Date: 2017-02-15
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 0187-0004-00 [00187000400]

Siliq INJECTION

• Marketing Category: BLA
• Application Number: BLA761032
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2017-02-15

NDC 0187-0004-02 [00187000402]

Siliq INJECTION

• Marketing Category: BLA
• Application Number: BLA761032
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2017-02-15

Drug Details

Active Ingredients

Ingredient	Strength
BRODALUMAB	210 mg/1

OpenFDA Data

• SPL SET ID: 1a550c33-456a-4833-814e-8591aea7c688
• Manufacturer:
  • Valeant Pharmaceuticals North America LLC
• UNII:
  • 6ZA31Y954Z
• RxNorm Concept Unique ID - RxCUI:
  • 1872256
  • 1872261

Pharmacological Class

• Interleukin-17 Receptor A Antagonist [EPC]
• Interleukin 17 Receptor A Antagonists [MoA]
• Antibodies
• Monoclonal [CS]